CDC7 激□抑制剂:全球临床试验与市场机会 (2024)
市场调查报告书
商品编码
1378355

CDC7 激□抑制剂:全球临床试验与市场机会 (2024)

Global CDC7 Kinase Inhibitors Clinical Trials & Market Opportunity Insight 2024

出版日期: | 出版商: KuicK Research | 英文 60 Pages | 商品交期: 最快1-2个工作天内

价格

CDC7激□最有前途的原因之一是它作为癌症药物标靶的潜力。癌细胞不受控制的增殖通常涉及 DNA 复製失调,且 CDC7 激□通常在各种癌症类型中过度表达。抑制 CDC7 激□会抑制复製过程,导致 DNA 损伤最终导致细胞死亡。因此,预计靶向 CDC7 激□将能够阻止癌症进展。CDC7 激□抑制剂专注于抑制 DNA 复製过程,因此有可能提供一种更特异、毒性更小的方法。

除了癌症之外,CDC7激□在发炎和病毒性疾病的治疗中也引起了人们的关注。发炎性疾病通常涉及过度的细胞增殖,调节 CDC7 激□可以抑制这种增殖并减轻发炎反应。此外,有些病毒,特别是DNA病毒,利用宿主细胞的DNA复製机制进行自身复製。此外,最近的研究表明,某些病毒(例如阿比病毒属病毒)使用 CDC7 磷酸化 VP3,从而增强病毒的复製能力。抑制 CDC7 激□有可能阻止病毒复製,从而提供一种新的抗病毒治疗方法。

此外,研究表明,将 CDC7 激□抑制剂与现有的癌症化疗相结合可能会提高疗效。这些治疗方法的结合可以解决癌细胞的异质性,并为癌症治疗提供全面的解决方案。CDC7 激□在特定癌症类型中的过度表达可以实现个人化的治疗方法。这意味着 CDC7 激□过度表达的患者可能会从客製化治疗中受益匪浅。

製药公司已经认识到 CDC7 激□的潜力,并正在积极开发针对该标靶的抑制剂,多项临床试验正在进行中。随着临床试验的进展,CDC7激□作为抗癌药物标靶、抗发炎标靶和抗病毒工具的前景越来越光明。该领域的持续研发有可能彻底改变癌症治疗、发炎性疾病治疗和抗病毒策略。

本报告探讨了 CDC7 激□抑制剂的临床试验趋势和市场机会,总结了按公司、适应症和阶段划分的临床管道、按国家/地区划分的趋势、发展驱动因素和挑战以及竞争格局。

目录

第一章 CDC7 激□抑制剂:简介

第二章全球 CDC7 激□抑制剂市场与临床趋势:依适应症分类

  • 白血病
  • 大肠直肠癌
  • 胰臟癌

第三章 全球CDC7抑制剂市场展望

  • 当前市场前景
  • 未来市场机会

第 4 章 CDC7 激□抑制剂市场趋势:按地区

  • 中国
  • 日本
  • 英国
  • 美国

第五章 全球CDC7蛋白激□抑制剂临床试验概况

  • 按国家
  • 适应症
  • 阶段
  • 治疗班

第六章 CDC7蛋白激□抑制剂的全球临床管线:依公司、适应症和阶段分类

  • 第一阶段
  • 一期/二期

第七章全球 CDC7 激□抑制剂市场:市场动态

  • 市场驱动力
  • 市场挑战

第八章 竞争格局

  • Carna Biosciences
  • Chia Tai Tianqing Pharmaceutical Group
  • Eli Lilly
  • Memorial Sloan-Kettering Cancer Center
  • Schrodinger

“Global CDC7 Kinase Inhibitors Clinical Trials & Market Opportunity Insight 2024” Report Highlights:

  • Global CDC7 Kinase Inhibitors Clinical Pipeline By Company, Indication & Phase
  • Highest Clinical Phase: Phase-I/II
  • US Dominating Global CDC7 Kinase Inhibitors Clinical Trials
  • Global CDC7 Inhibitors Market Current & Future Outlook
  • CDC7 Kinase Inhibitors Development Trends by Country
  • Competitive Landscape

Kinase proteins are targets of upmost importance in the realm of cancer therapeutics because of their ubiquitous roles in numerous cell processes. Research on kinases has spanned several decades, and in the process, a large number of kinases have been identified. One of these, discovered in the early 1970s, is the cell division cycle 7-related protein kinase, or the CDC7 kinase protein that is encoded by the CDC7 gene. Similar to other kinase proteins, CDC7 is needed for several cell processes, including replication, which has brought it into the limelight as another targetable protein for the development of cancer chemotherapies. Despite years of studies, researchers are still trying to understand the function and therapeutic potential of CDC7; however, a couple pharmaceutical companies are already making strides in the pharmaceutical market with their CDC7-inhibiting candidates in development and clinical evaluation.

CDC7 is a serine-threonine kinase. Its significance in the replication process was initially demonstrated using mouse embryonic stem cells, where DNA synthesis was inhibited in the absence of CDC7, resulting in the halting of the S phase at the G2-M DNA damage checkpoint to prevent mitosis with the damaged or incomplete DNA. CDC7 is therefore essential for the initiation of DNA replication process, making it a potential target for various therapeutic applications. CDC7 kinase functions in collaboration with tits regulatory subunit DBF4, forming the CDC7-DBF4 complex. This complex helps regulate the formation of the DNA replication origins, ensuring proper DNA replication and cell division.

One of the most promising aspects of CDC7 kinase is its potential as a cancer drug target. The uncontrolled proliferation of cancer cells often involves dysregulation of DNA replication, and CDC7 kinase is often overexpressed in various cancer types. Inhibition of CDC7 kinase can disrupt the replication process, leading to DNA damage and ultimately, cell death. As a result, targeting CDC7 kinase holds great promise in halting the progression of cancer. Traditional cancer therapies, such as chemotherapy and radiation, target rapidly dividing cells. In contrast, CDC7 kinase inhibitors focus on disrupting DNA replication process, offering a more specific and potentially less toxic approach.

Beyond cancer, CDC7 kinase is also gaining attention for its role in treating inflammatory and viral diseases. Inflammatory diseases often involve excessive cell proliferation, and the modulation of CDC7 kinase can potentially reduce this proliferation, mitigating the inflammatory response. Additionally, some viruses, particularly DNA viruses, reply on host cell DNA replication machinery for their own replication. Moreover, in a recently conducted study, it was shown that certain viruses, like Avibirnavirus, use the CDC7 to phosphorylate the VP3, enhancing the replication ability of the virus. By inhibiting CDC7 kinase, it may be possible to thwart viral replication, offering a new approach in antiviral therapies.

Inhibition of CDC7 offers potential benefits over other cancer therapies. The CDC7 kinase is involved in the DNA replication initiation, and inhibiting it is expected to have minimal off-target interactions, compared to other broadly targeted therapies. In addition, combining CDC7 kinase inhibitors with existing cancer chemotherapies has shown potential for enhanced efficacy in research studies. The combination of these therapies may provide a comprehensive solution to cancer treatment, addressing the heterogeneity of cancer cells. The overexpression of CDC7 kinase in specific cancer types allows for a personalized approach to treatment. So, patients with CDC7 kinase overexpression could benefit significantly from tailored therapies.

Pharmaceutical companies have recognized the potential of CDC7 kinase and are actively developing inhibitors for this target, with a few clinical trials. As clinical trials progress, the future of CDC7 kinase as a cancer drug target, anti-inflammatory target, and antiviral tool is becoming increasingly promising. The continued research and development in this field hold the potential to revolutionize cancer therapy, inflammatory disease treatment and antiviral strategies.

CDC7 kinase is developing as an intriguing player in the pharmaceutical sector, with substantial potential in the treatment of cancer, inflammatory processes, and viral diseases. Its specificity, synergy with existing therapies, and personalized treatment options make it a compelling choice for researchers and clinicians alike. As pharmaceutical companies invest in the development of CDC7 kinase inhibitors, the coming years look bright for this remarkable protein kinase, paving the way for innovative and effective therapeutic options.

Table of Contents

1. Brief Introduction To CDC7 Kinase Inhibitors

  • 1.1. Overview
  • 1.2. History & Emergence of CDC7 Kinase Inhibitors

2. Global CDC7 Kinase Inhibitors Market & Clinical Trends by Indications

  • 2.1. Leukemia
  • 2.2. Colorectal Cancer
  • 2.3. Pancreatic Cancer

3. Global CDC7 Inhibitors Market Outlook

  • 3.1. Current Market Outlook
  • 3.2. Future Market Opportunity

4. CDC7 Kinase Inhibitors Market Trend By Region

  • 4.1. China
  • 4.2. Japan
  • 4.3. UK
  • 4.4. US

5. Global CDC7 Protein Kinase Inhibitors Clinical Trials Overview

  • 5.1. By Country
  • 5.2. Indication
  • 5.3. Phase
  • 5.4. Therapy Class

6. Global CDC7 Protein Kinase Inhibitors Clinical Pipeline By Company, Indication & Phase

  • 6.1. Phase-I
  • 6.2. Phase-I/II

7. Global CDC7 Kinase Inhibitor Market Dynamics

  • 7.1. Market Drivers
  • 7.2. Market Challenges

8. Competitive Landscape

  • 8.1. Carna Biosciences
  • 8.2. Chia Tai Tianqing Pharmaceutical Group
  • 8.3. Eli Lilly
  • 8.4. Memorial Sloan-Kettering Cancer Center
  • 8.5. Schrodinger

List of Figures

  • Figure 1-1: CDC7 Kinase Inhibitor - Mechanism of Action
  • Figure 1-2: Comparison of CDC7 Inhibitors With Conventional Methods
  • Figure 1-3: CDC7 Inhibitor Development
  • Figure 2-1: LBS-007 Phase I/II Study - Initiation & Completion Year
  • Figure 2-2: Schrodinger Drug Discovery Approach
  • Figure 2-3: SGR-2921 Phase I Study - Initiation & Completion Year
  • Figure 2-4: TAK-931 Phase II Trials Commencement
  • Figure 2-5: Ongoing CDC7 Inhibitors Candidates - Mode Of Action
  • Figure 2-6: LY3143921 hydrate Phase I Study - Initiation & Completion Year
  • Figure 2-7: TQB3824 Phase I Study - Initiation & Completion Year
  • Figure 2-8: CDC7 Inhibitor For The Treatment Of Pancreatic Cancer
  • Figure 3-1: Global CDC7 Inhibitor - Current Ongoing Candidates In Trials
  • Figure 3-2: Global CDC7 Inhibitors Market - Future Aspects
  • Figure 4-1: Candidates Developed By Nerviano Medical Science
  • Figure 4-2: Aspects For The Inclining Growth Of CDC7 Inhibitors In China
  • Figure 4-3: AS-0141: Mechanism Of Action
  • Figure 4-4: Timeline Of AS-0141
  • Figure 4-5: Ongoing Research Conducted By Cancer Research Horizon
  • Figure 4-6: US - Cancer Incidences & Deaths, 2023
  • Figure 5-1: Global - CDC7 Protein Kinase Inhibitors Clinical Trials by Country (Numbers), 2023 & 2024
  • Figure 5-2: Global - CDC7 Protein Kinase Inhibitors Clinical Trials by Indication (Numbers), 2023 & 2024
  • Figure 5-3: Global - CDC7 Protein Kinase Inhibitors Clinical Trials by Phase (Numbers), 2023 & 2024
  • Figure 5-4: Global - CDC7 Protein Kinase Inhibitors Clinical Trials by Therapy Class (Numbers), 2023 & 2024
  • Figure 7-1: Global - CDC7 Inhibitor Market Drivers
  • Figure 7-2: Global - CDC7 Inhibitor Market Challenges

List of Tables

  • Table 2-1: Leukemia Cancer - CDC7 Kinase Inhibitor Ongoing Clinical Trials
  • Table 2-2: Colorectal Cancer - CDC7 Kinase Inhibitor Ongoing Clinical Trials
  • Table 2-3: Pancreatic Cancer - CDC7 Kinase Inhibitor Ongoing Clinical Trials
  • Table 4-1: China - CDC7 Kinase Inhibitor Ongoing Preclinical & Clinical Trials
  • Table 4-2: Japan - CDC7 Kinase Inhibitor Ongoing Clinical Trials
  • Table 4-3: UK - CDC7 Kinase Inhibitor Ongoing Clinical Trials